Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC)
Open Access
- 1 January 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (1) , 12-21
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Whole genome–amplified DNA: insights and imputationNature Methods, 2008
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2007
- Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersLung Cancer, 2007
- Molecular Diagnostics in Advanced NSCLC: Trying to Maximize a Non-Ideal SituationJournal of Thoracic Oncology, 2007
- PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)Journal of Thoracic Oncology, 2007
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLOS Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colonNature Genetics, 1994
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987